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Zaleplon (ZP) is a sedative and hypnotic drug used for the treatment of insomnia.
Despite its potent anticonvulsant activity, ZP is not commonly used for the treat-
ment of convulsion since ZP is characterized by its low oral bioavailability as a result
of poor solubility and extensive liver metabolism. The following study aimed to
formulate specifically controlled release nano‐vehicles for oral and parenteral de-
livery of ZP to enhance its oral bioavailability and biological activity. A modified
single emulsification–solvent evaporation method of sonication force was adopted
to optimize the inclusion of ZP into biodegradable nanoparticles (NPs) using poly
(dl‐lactic‐co‐glycolic acid) (PLGA). The impacts of various formulation variables on
the physicochemical characteristics of the ZP‐PLGA‐NPs and drug release profiles
were investigated. Pharmacokinetics and pharmacological activity of ZP‐PLGA‐NPs
were studied using experimental animals and were compared with generic ZP
tablets. Assessment of gamma‐aminobutyric acid (GABA) level in plasma after oral
administration was conducted using enzyme‐linked immunosorbent assay. The
maximal electroshock‐induced seizures model evaluated anticonvulsant activity
after the parenteral administration of ZP‐loaded NPs. The prepared ZP‐PLGA NPs
were negatively charged spherical particles with an average size of 120–300 nm.
Optimized ZP‐PLGA NPs showed higher plasma GABA levels, longer sedative,
hypnotic effects, and a 3.42‐fold augmentation in oral drug bioavailability in com-
parison to ZP‐marketed products. Moreover, parenteral administration of ZP‐NPs
showed higher anticonvulsant activity compared to free drug. Oral administration of
ZP‐PLGA NPs achieved a significant improvement in the drug bioavailability, and
parenteral administration showed a pronounced anticonvulsant activity.
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1 | INTRODUCTION
Zaleplon (ZP) is commonly used as a sedative and hypnotic drug with
potent anticonvulsant activity. The pharmacological effect of ZP is
correlated to its agonist effect on the gamma‐aminobutyric acid‐A
(GABA‐A) (type 1) receptor, specifically, benzodiazepine binding
sites (Dooley & Plosker, 2000). Based on the biopharmaceutical
classification system, ZP is categorized as a Class II drug with poor
aqueous solubility and high intestinal permeability. It exhibits a
relatively low oral bioavailability of about 30% (Drover, 2004). The
low oral bioavailability is a result of combined poor dissolution and
extensive first‐pass metabolism (Waghmare, Pore, & Kuchekar,
2008). Zaleplon is marketed in two dosage forms: tablets and cap-
sules. However, the oral route of ZP faces numerous obstacles that
hinder its oral delivery. The poor aqueous solubility slows down its
dissolution with subsequent augmentation of its hepatic metabolism
(Dudhipala, 2016). This leads to a disturbance in drug pharmacoki-
netic represented by delayed onset of action, short elimination T1/2
(1 h), and short duration of action. Therefore, ZP fails to keep its
pharmacological activity reasonable, resulting in early morning
awakening (Farag, El Malak, & Yehia, 2018). Increasing the dose of
ZP to overcome low oral bioavailability is not recommended because
it is related to typically short‐lived hallucinations (Farag et al., 2018).
ZP is not among the most often prescribed sedative and hypnotic
because it has a quick onset of action and very short elimination
half‐life of approximately 1 h (Terzano, Rossi, Palomba, Smerieri, &
Parrino, 2003). The drug exerts a better action on sleep induction
rather than sleep maintenance due to its short half‐life and quick
onset of action. Previous studies showed that zaleplon has a
nonsignificant effect on the total sleep time and the number of
awakenings (Sateia, Buysse, Krystal, Neubauer, & Heald, 2017).
Different formulation approaches were used to optimize the oral
delivery of ZP. These approaches vary between solid dispersion
(Waghmare, Pore, & Kuchekar, 2008), micronization (Manda et al.,
2018), proliposome (Janga et al., 2012), self‐nanoemulsifying pow-
ders (Janga et al., 2013), and solid lipid nanoparticles (Dudhipala &
Janga, 2017).
Nanotechnology has been revolutionized the field of drug de-
livery and targeting regarding its supernatural qualities such as small
particle size (PS), high exposed surface area, improved physical and
chemical stability, and the high biocompatibility of its ingredients
(Baker, 2006). Moreover, nanotechnology can optimize the solubility,
dissolution, permeability, and bioavailability of several drugs
regardless of their physical properties (Card & Magnuson, 2011).
Nanotechnology compromises a wide range of formulation tech-
niques such as biodegradable polymeric nanoparticles (PNPs), lipid
nanoparticles, magnetic nanoparticles, polymeric micelles, liposomes,
niosomes, and nanoemulsion (Brigger, Dubernet, & Couvreur, 2002).
PNPs are colloidal solid particles consisting of natural or syn-
thetic biocompatible polymers formulated into nanoscale particles.
PNPs enjoy great popularity among previously discussed nano-
systems for many reasons. First of all, its ease of formulation involves
only three simple steps. Second, the simplicity of adjusting and
controlling its physicochemical characteristics during formulation.
Also, the vast diversity of available polymers can offer a wide range
of physicochemical characteristics that can be tailored depending on
the desired effect (Haggag et al., 2016; Haggag & Faheem, 2015;
Kamaly, Xiao, Valencia, Radovic‐Moreno, & Farokhzad, 2012; Khan,
Haggag, Lane, McCarron, & Tambuwala, 2018).
PNP drug delivery systems can improve the oral bioavailability of
poorly soluble drugs, sustain its biological activity, and improve drug
stability (Haggag et al., 2020a). Modulation of polymer physico-
chemical characteristics enabled us to achieve optimal therapeutic
efficacy by controlling the optimum release of a therapeutic agent for
the required duration needed for attaining the desired therapeutic
level in target tissues (Khan et al., 2018).
Moreover, polymeric NP systems may be able to overcome the
limitations of nanoemulsions and solid lipid nanoparticles. The
major drawbacks of nanoemulsion include low shelf‐life stability
due to thermodynamics and Ostwald ripening and difficulty in
preparation and scale‐up production. Formulation of nanoemulsions
needs high concentrations of surfactant and cosurfactant necessary
for improving the nanoemulsion stability (Patel, Patel, & Thakore,
2018; Yukuyama, Kato, Lobenberg, & Bou‐Chacra, 2017). However,
solid lipid nanoparticles showed some other disadvantages such as
the propensity of lipid oxidation and transformation, incompatibility
with various active agents, and a limited drug loading efficiency
(Deshpande et al., 2017; Ghasemiyeh & Mohammadi‐Samani, 2018).
In contrast, polymeric nanocarriers are more stable in vivo, with
high drug loading capacities, as well as controlled or triggered
release of drugs (Kamaly et al., 2012). According to these unique
properties, polymeric nanomaterials are well positioned in our
study to provide a novel solution for ZP oral and parenteral
delivery.
Oral delivery is a standard route for drug administration due to
its favorable advantages of high patient compliance due to self‐
administration ease. However, some physiological barriers control
drug bioavailability and therapeutic activity (Bakhru, Furtado,
Morello, & Mathiowitz, 2013). The formulation of PNPs is a prom-
ising approach to handle these physiological obstacles and enhance
the gastrointestinal absorption of drugs with limited aqueous solu-
bility (Jung et al., 2000). The impact of PNPs' size, shape, and
surface chemistry largely affects systemic drug delivery after oral
administration (Malhaire, Gimel, Roger, Benoît, & Lagarce, 2016).
Antiepileptic drugs can be administrated by different routes. The
oral route is the classic route for chronic treatment of epilepsy, but
it is challenging to be considered for the treatment of an epileptic
attack. Parental, rectal, buccal, and intranasal routes represent the
most common alternatives to oral administration, but each route
has its advantages and limitations. Parenteral administration is the
optimum solution for acute treatment due to the rapid onset of
action and successful drug delivery (Musumeci, Bonaccorso, &
Puglisi, 2019).
Among numerous existing polymers, poly (dl‐lactic‐co‐glycolic
acid) (PLGA) has acquired the interest of several researchers due to
its biodegradability, biocompatibility, sustained release profile, and
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maximum safety issues. PLGA is Food and Drug Administration
approved for many formulations for the control of prostate and
breast cancers (Crawford & Phillips, 2011; Kamaly et al., 2012). The
current study is the first to adopt the formulation of PLGA NPs
encapsulating ZP to investigate the bioavailability and pharmaco-
logical activity of ZP‐PLGA NPs in vivo following oral or parenteral
administration.
The following study aimed to inspect the role of PNPs in
enhancing the oral administration of ZP as a sedative and hypnotic
drug. Besides, improving the anticonvulsant activity after parenteral
administration. The effect of various formulation variables, such as
the polymer amount, stabilizer concentration, and sonication time, on
the characteristics of the nanoparticles, release profiles, in vivo
pharmacokinetic behavior, and in vivo biological activity of encap-
sulated ZP were investigated in this study.
2 | MATERIALS AND METHODS
2.1 | Materials
PLGA (50:50) (Resomer® RG 503H, MW34 kDa), ZP, polyvinyl
alcohol (PVA, 87%–89% degree of hydrolysis, molecular weight
31,000–50,000), phosphate‐buffered saline (PBS), dichloromethane
(DCM), and acetonitrile were purchased from Sigma‐Aldrich Chemi-
cal Co. All other reagents were of high analytical grade.
2.2 | Fabrication of ZP‐PLGA polymeric
nanoparticles
ZP‐PLGA PNPs were formulated via a simple emulsification–solvent
evaporation technique (Khan et al., 2018). To sum up, ZP and PLGA
were dissolved in a common organic solvent (DCM) that can dissolve
both completely. The selected organic solvent is characterized by its
low boiling point, high volatility, high dissolving power, and water
immiscibility. The aqueous phase compromised PVA as a stabilizer.
The emulsification process was conducted via an ultrasonic
homogenizer with a 3.2‐mm probe (Cole‐Parmer) to form o/w
nanoemulsion. ZP‐PLGA PNPs were formed after the evaporation of
DCM overnight using magnetic stirring. Finally, NPs were separated
by ultra‐centrifugation at 30,000g for 30 min with a cooling centri-
fuge (Sigma Laborzentrifugen GmbH.), followed by three times of
washing with ultrapure water and 2% w/v sucrose solution and
lyophilized (Labconco). The final product of ZP‐PLGA NPs was kept in
a desiccator at room temperature. The formulation parameters and
identifier codes are listed in Table 1.
2.3 | In vitro physicochemical characteristics of ZP‐
PLGA NPs
2.3.1 | Particle size (PS) and polydispersity index
(PDI)
PS and polydispersity index (PDI) were estimated with the aid of the
dynamic light scattering principle (Malvern Zetasizer 5000). Briefly, 1
µl of nanosuspension was diluted at 1:10 ratio with Milli‐Q® water
after vortexing and sonication. Measurements were recorded as
triplicates.
2.3.2 | Zeta potential
ZP was recorded using the same equipment of PS and PDI (Malvern
Zetasizer 5000). Electrophoretic mobility was used to determine the
surface charges of ZP‐PLGA NPs. Measurements were represented
as triplicates.
2.3.3 | Surface morphology
Nanoparticles' surface morphology was observed by scanning elec-
tron microscope (SEM) on an FEI Quanta 400 FEG SEM (FEI). The
samples were sited onto metal stubs and layered with a gold coat
under vacuum before observation under an electron microscope.



















F1 PLGA 2.5 0.5 1 5 1:10
F2 PLGA 5 0.5 1 5 1:10
F3 PLGA 10 0.5 1 5 1:10
F4 PLGA 10 1 1 5 1:10
F5 PLGA 10 1.5 1 5 1:10
F6 PLGA 10 1.5 2 5 1:10
F7 PLGA 10 1.5 3 5 1:10
Abbreviations: NPs, nanoparticles; ZP‐PLGA, zaleplon‐poly (dl‐lactic‐co‐glycolic acid); PVA, polyvinyl alcohol; PLGA, poly (dl‐lactic‐co‐glycolic acid).
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2.3.4 | Entrapment efficiency
The entrapment efficiency (%E.E) of ZP was evaluated by an indi-
rect measurement method. The supernatant containing the non‐
entrapped drug was collected after centrifugation of NPs and used
to quantify the free drug using the reversed‐phase high‐pressure
liquid chromatography (HPLC) method (Metwally, Abdelkawy, &
Abdelwahab, 2007). In detail, the HPLC system consisted of an
autosampler (Waters® 717), a controller (Waters® 600), and a
tunable absorbance UV detector (Waters® 486). The mobile phase
composed of acetonitrile and water (35:65%) and pumped at a rate
of 1 ml/min. The amount of ZP was monitored spectrophotomet-
rically at 232 nm. %E.E was measured by excluding the amount of
free ZP from the total amount of ZP and the results were evaluated
as triplicates:
% Entrapment efficiency ¼




2.4 | In vitro release study
The release ZP from ZP‐PLGA NPs was conducted via the dialysis
process (Haggag et al., ; Haggag, Ibrahim, & Hafiz, 2020c). Four mil-
liliters of NP suspension was put into a 5‐cm dialysis sac (spectra‐por,
cut‐off 12–14 KDa). The dialysis membrane containing the NPs was
immersed into 50 ml of PBS release media (pH ¼ 7.4). The medium
was stirred at 100 rpm and kept warm at 37 � 2°C using a magnetic
stirrer. After each time interval, a 1 ml withdrawn sample was
collected and refilled with 1 ml of fresh PBS. The analysis of ZP
concentration was performed using the previously discussed HPLC
method.
2.5 | In vivo study
2.5.1 | Bioavailability study
Healthy 24 male albino rabbits weighing 1.8–2 kg were used in the
present study. The rabbits were held in fasting condition for 24 h
previously, and the rabbits were categorized into four different
groups, each containing six rabbits. Group 1 was treated orally by
normal saline and served as control, whereas group 2 received a
marketed ZP tablet (reference) at a dose of 1 mg·kg  1 (Hosny &
Banjar, 2013; Noguchi, Kitazumi, Mori, & Shiba, 2004). Group 3 and
group 4 were administered orally with the same dose of ZP free
suspension and ZP‐PLGA NPs (F5), respectively. Two milliliters of
blood samples were collected at 0, 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24 h
after oral intake of the drug. Samples were preserved at   20°C until
analysis. Blood samples were centrifuged at 4000 rpm for 30 min with
subsequent measurement of ZP concentration using the adopted
HPLC method. The pharmacokinetics parameters (PK) (Cmax and Tmax,
area under curve [AUC], mean residence time (MRT), and T1/2) were
measured using the plasma concentration–time curve using the
WinNonlin® Nonlinear Estimation Program. All experimental works
were under the ethical committee of the School of Pharmacy, Tanta
University, Egypt.
2.5.2 | Assessment of GABA level in rabbits' plasma
Along with the pharmacokinetic study, rabbits were used to measure
the gamma‐aminobutyric acid (GABA) level in the plasma. After 3 h of
dose administration, blood samples from all animal groups were
collected and centrifuged. The plasma GABA level for each rabbit was
estimated using the GABA Elisa kit (Rabbit GAMA Enzyme‐Linked
Immunosorbent Assay [ELISA] Kit, Catalog No. MBS722440,
MyBioSource Inc.).
2.5.3 | Sedative and hypnotic action
The sedative and hypnotic effect of ZP was interestingly investigated
through the measurement of the effect of ZP and ZP‐PLGA NPs on
sedation and hypnosis of rabbits (Bellini, Banzato, Contiero, & Zotti,
2014). Simply, the onset of sedation and hypnosis and duration of
hypnosis were measured for all animal groups before starting the PK
study. Regular observation for all animals was done to record the
time needed for hypnosis and hypnosis duration for each animal. All
experimental works were conducted in agreement with the research
ethics guidelines conditioned by the Faculty of Pharmacy, Tanta
University, Egypt.
2.5.4 | Evaluation of anticonvulsant activity
Anticonvulsant activity of free ZP and ZP‐loaded NPs was evaluated
by maximal electroshock‐induced seizure (MES) model in vivo. Thirty
albino rats were used for this study. Rats were classified into three
groups (10 rats/group): the first group received the saline and served
as the control animal group; the second group was treated with ZP
suspension (20 mg/kg); and the third group received the nano-
suspension of ZP‐PLGA NPs of the same dose of (20 mg/kg). Maximal
electroshock (MES; 60Hz, 0.2 s, 150mA)was carried through auricular
(ear lobe) electrodes using electroconvulsive therapy unit (Ugo Basile).
TheMES study was conducted 10 h following intraperitoneal injection
of drug treatments. Seizure severity was scored and recorded. The
evaluation was based on the extent of tonic–clonic seizure and the
extent of tonic extension spread. The scoring system was reported
(Wang et al., 2016). The length of tonic extension and occurrence of
tonic seizures were also examined as measures of seizure severity
(Wang et al., 2016).
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2.6 | Statistical analysis
PS, zeta potential, entrapment efficiency, and drug release were
presented as mean � standard deviation (SD) and treated statistically
using one‐way analysis of variance (ANOVA) followed by post hoc
Tukey's test. The results of in vivo studies were demonstrated as
mean � SEM and treated statistically using one‐way ANOVA fol-
lowed by post hoc Tukey's test. The AUC analysis was conducted
using trapezoidal rule with baseline correction. p < 0.05 was
considered statistically significant.
3 | RESULTS AND DISCUSSION
The current study was conducted to investigate the impact of
different formulation variables on the various characteristics of the
ZP nanoparticles, such as nanoparticles size, surface morphology, and
entrapment efficiency. In vitro release to optimize the fabrication of
ZP‐PLGA NPs having an appropriate size and high drug loading for
controlled pharmacological action was investigated.
3.1 | Influence of polymer concentration
The effect of different PLGA amounts on the physicochemical char-
acteristics of ZP‐PLGA NPs (F1, F2, and F3) was demonstrated in
Figure 1. PLGA‐ZP nanoparticle sizes were significantly (p ˂ 0.05)
increased by the increase of polymer concentration in DCM from 2.5%
w/v to 5% and 10%w/v (Figure 1a). The possible reported explanation
of this finding could be due to the higher viscosity of the organic phase.
There is an integral correlation between PS and viscosity of both
phases (aqueous and organic phases). Provided that the shear stress is
a constant, an increase in the viscosity causes a considerable increase
in the resistance to the exposed shear stress. Consequently, the
probability of coalescence between nanoparticles during formulation
is increased. The balance between agitation shear force and droplet
cohesion during the processing of nanoparticles controls the size of
formed emulsion droplets (Fude et al., 2005; Haggag et al., 2018a).
Concerning zeta potential, increasing the concentration of poly-
mer to 10% w/v is followed by a significant (p ˂ 0.01) increase in zeta
potential, whichmight be discussed by the intense polymer abundance
on nanoparticles' surface following the increase in polymer concen-
tration (Khan et al., 2018). The change in polymer concentration from
2.5% w/v to 5% w/v did not record a significant increase (p ˃ 0.05) in
nanoparticles' surface charge in case of (F1, F2) (Figure 1b).
Drugencapsulationefficiencywas significantly (p˂0.05) enhanced
by changing the concentration of polymer from 2.5%w/v (F1) to 5%w/
v (F2) and 10% (F3) (Figure 1c). Improvement of ZP entrapment effi-
ciency could be also attributed to the higher viscosity of the oily phase
with subsequent enlargement of emulsion droplet size that created a
more stable microenvironment to prevent drug escape from the
organic phase to the exterior aqueous media. Another possible
explanation is the rapid solidification of polymer following the increase
in the polymer concentration that restricts drug diffusion from the
inner oily phase (Haggag et al., 2016; Yang, Chung, Bai, & Chan, 2000).
The effect of different concentrations of PLGA on the ZP release
was shown in (Figure 1d). The early burst effect was interestingly
affected by changing PLGA concentrations. A significant (p ˂ 0.05)
decline in initial burst release from 24% (F1) to 36% (F3) was detected.
Thismaybe clarifiedby the fast solidification process that followeddue
to the high polymer concentration; the polymer matrix will become
condensed, resulting in smaller pores and a further tortuous assembly
because of the chain entanglement, which obstructs drug transmission
to release media (Yang, Chung, & Ng, 2001).
F I G U R E 1 Effects of the polymer
concentration on nanoparticle size (a), zeta
potential (b), encapsulation efficiency (c) and
zaleplon in vitro release (d). Values are
mean � standard deviation for (n ¼ 3). For a–c,
*p < 0.05; **p < 0.01; ***p < 0.001, compared
with 2.5% w/v polymer concentration (F1).
Δp < 0.05 compared with 5% w/v polymer
concentration (F2)
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3.2 | Influence of the PVA concentration of the
aqueous phase
PVA is a frequently used stabilizer in the fabrication of biodegradable
PNPs. PVA concentration in the aqueous phase predominately con-
trols nanoparticles' size (Haggag et al., 2018a, 2018b; Sahoo, Panyam,
Prabha, & Labhasetwar, 2002). PVA was used at three different
concentrations of 0.5%, 1%, and 1.5% w/v as a stabilizer in the
aqueous phase to study the effect of PVA concentration on the
physicochemical characteristics of different ZP‐PLGA NPs formula-
tions of (F3, F4, and F5) as summarized in Figure 2.
A significant (p ˂ 0.05) reduction in nanoparticle size of F4 and
F5 was observed after altering the concentration of PVA in the
external phase (Figure 2a). This was endorsed to the fact that
increasing PVA concentration would raise the continuous aqueous
phase viscosity and successively the stability of emulsion droplets
formed during sonication. Increasing the emulsion stability in addi-
tion to the enhanced surfactant activity of PVA at higher concen-
trations prevented the coalescence of emulsion droplets. Therefore,
smaller droplets would progressively harden to form nanospheres
with a low PDI (Haggag et al., 2017; Sahoo et al., 2002).
Increasing the PVA concentration caused a significant (p ˂ 0.05)
decrease in zeta potential. PVA concentration of 0.5% (F3) showed
more intense negative zeta potential values concerning the higher
PVA concentration of 1% and 1.5% w/v (F4 and F5), respectively
(Figure 2b). This sharp drop in zeta potential values while increasing
PVA concentrations can be explicated by the coating of nanoparticles
with a residual PVA which covered the particle's charge and change
the shear plane outwards from the particle surface. 0.5% PVA con-
centration has the least shielding effect and, consequently, more
carboxyl groups are existing for ionization; therefore, the higher zeta
potential was obtained (Haggag et al., 2017). Moreover, a significant
(p ˂ 0.05) increase in ZP encapsulation and drug loading was detected
after increasing the concentration of PVA in the outer water phase
from 0.5% to 1.5% w/v in the case of PLGA nanoparticles (Figure 2c).
This effect might be explained by two hypotheses. First, the increased
viscosity of the aqueous phase minimizes the drug transport from the
organic phase to the outer aqueous phase. Secondly, the higher PVA
concentration resulted in a higher amount of PVA at the interface,
which serves as a barrier between the organic aqueous phase that
contributed to higher resistance against drug transmission out of the
organic phase leading to higher drug loading (Haggad et al., 2016;
Khan et al., 2017). However, increasing the concentration of PVA
from 0.5% w/v to 1% w/v give rise to nonsignificant (p ˃ 0.05) change
in encapsulation efficiency. This might be attributed to lower vis-
cosity of 0.5% and 1% w/v PVA solutions in contrast to 1.5% PVA
concentration (Sahoo et al., 2002).
Release behavior of ZP‐PLGA NPs formulated with 0.5%, 1%,
and 1.5% w/v of PVA were demonstrated in (Figure 2d). The release
pattern of (F3) formulated with 0.5% w/v PVA showed a significant
(p ˂ 0.05) lower initial burst effect concerning (F4 and F5) prepared
with 1% and 1.5% w/v PVA. As long as the burst release was linked to
the diffusion of the surface‐attached drug, a higher PVA concentra-
tion of 1.5% resulted in smaller nanoparticles with higher surface
area readily exposed to the media of release which facilitate ZP
diffusion and release (Fude et al., 2005; Haggag et al., 2016).
3.3 | Influence of sonication time
The physicochemical characteristics of three different formulations
of ZP‐PLGA NPs (F5, F6, and F7) made using three different
F I G U R E 2 Effects of the polyvinyl alcohol
(PVA) concentration on nanoparticle size (a),
zeta potential (b), encapsulation efficiency
(c) and zaleplon in vitro release (d). Values are
mean � standard deviation for (n ¼ 3). For a–c,
*p < 0.05, **p < 0.01, ***p < 0.001 compared
with 0.5% w/v PVA concentration (F3).
Δp < 0.05 compared with 1% w/v PVA
concentration (F4)
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sonication times are presented in Figure 3. ZP‐loaded PLGA nano-
particles (F7) prepared by using the longest sonication time of 3 min
were significantly (p ˂ 0.05) smaller in size than the nanoparticles (F5
and F6) prepared by using 1 and 2 min sonication time, respectively.
Increasing the sonication time produced a decrease in the PS of
F7 (Figure 3a). These findings might be attributed to the higher shear
stress used, which would create a suitable condition to prevent
coalescence of emulsion droplets resulting in reduced emulsion
droplets, which in turn led to smaller nanoparticles (Haggag et al.,
2018). Increasing the sonication time from 1 min to 3 min did not
count for a significant (p ˃ 0.05) change in nanoparticles' zeta po-
tential (Figure 3b). However, a sharp (p ˂ 0.05) decrease in drug
encapsulation efficiency was observed in F6 and F7 compared to F5
(Figure 3c). Increasing sonication time resulted in lower drug
entrapment. This might be explained by the effect of high shear
stress on polymer behavior with disruption of polymeric inner
structure and PVA interfacial layer, which facilitates drug diffusion to
the aqueous layer (Blum & Saltzman, 2008; Haggag et al., 2018a).
The release profile of (F5, F6, and F7) showed that the drug burst
release was faster and efficiently higher from F6 and F7 which
released almost 43% and 58% of ZP releases within the initial 24 h on
the contrary to 38% of drug released from the F5, respectively
(Figure 3d). The burst release effect is linked to the proportion of the
drug that attached the nanoparticle surface (Essa, Rabanel, &
Hildgen, 2010). A higher amount of drug was attached to F6 and F7
nanoparticle surfaces compared to F5 because of their smaller PS
and higher surface areas. Increasing sonication time leads to the
formation of a large number of pores inside the polymeric matrix and,
consequently, the drug can quickly diffuse through these pores to the
release medium (Bilati, Allemann, & Doelker, 2003).
Screening the previous results, we concluded that F5 showed the
highest encapsulation efficiency with a small nanoparticle size of
approximately 200 nm, a moderate zeta potential of   17.5 mV, the
highest entrapment efficiency of approximately 96%, and a relatively
low burst release of 38%. F5 was used as the optimized formula for
further characterization.
3.4 | Scanning electron microscopy
The SEM image of F5 was represented in Figure 4. ZP‐PLGA NPs had
a smooth sphere‐shaped appearance with very low PDI. Size mea-
surements by SEM and dynamic light scattering are highly correlated.
F I G U R E 3 Effects of the sonication time on
nanoparticle size (a), zeta potential (b),
encapsulation efficiency (c) and zaleplon in vitro
release (d). Values are mean � standard
deviation for (n ¼ 3). For a–c, *p < 0.05,
**p < 0.01, ***p < 0.001 compared with 1 min
sonication time (F5). Δp < 0.05 compared with 2
min sonication time (F6)
F I G U R E 4 Scanning electron microscope images of zaleplon–
poly (dl‐lactic‐co‐glycolic acid) nanoparticles (F5) after preparation
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3.5 | In vivo study
3.5.1 | Pharmacokinetic study
Zaleplon, being a class II drug, has a poor oral bioavailability as a
result of limited water solubility and extensive hepatic metabolism.
The mean plasma concentration versus time profiles of ZP after oral
intake of ZP free suspension, ZP marketed tablet, and ZP‐PLGA NPs
are demonstrated in Figure 5. The measured pharmacokinetic pa-
rameters are presented in Table 2. The pharmacokinetic study out-
comes clarified that oral delivery of ZP‐PLGA NPs (F5) can efficiently
alter its pharmacokinetic profile by increasing its bioavailability as
compared to the marketed oral tablet and free ZP suspension.
Following oral administration, plasma concentrations of ZP‐PLGA
NPswere all significantly (p ˂ 0.05) advanced than that of the free drug
and marketed tablet at every time point. Plasma concentration–time
curve showed the Cmax for ZP‐PLGA NPs (29.31 � 3.08 ng/ml) was
significantly (p ˂ 0.001) higher concerning marketed ZP tablet
(10.86 � 2.05 ng/ml) and free drug suspension (13.27 � 1.88 ng/ml).
However, the time to achieve the maximum plasma concentration
(Cmax)was shorter formarketedZP tablet andZPsuspensioncompared
to that of ZP‐PLGANPs. The total AUC, which represent the extent of
ZP absorption, was additionally significantly (p < 0.001) higher for ZP‐
PLGANPs (F5) (2135� 345 ng·h/ml) compared to marketed ZP tablet
(625�34.9 ng·h/ml) andZP suspension (802�65.6 ng·h/ml). TheMRT
and T1/2 weremore pronounced for F5 due to the slower elimination of
ZP from drug‐loaded PLGA NP formulation.
ZP‐PLGA NPs formulation exhibited a 3.42‐fold enhancement in
the oral bioavailability as compared to marketed ZP tablet and a
2.75‐fold increase over ZP suspension. The PK result illustrated that
Z‐PLGA NPs showed higher plasma concentration, lower clearance,
and a longer half‐life in comparison to ZP marketed tablet and ZP
suspension in rabbits. The smaller nanoparticle size of ZP‐PLGA NPs
with subsequent higher effective surface area, which further leads to
increased extent and duration of contact with gastro‐intestinal mu-
cosa with subsequent improvement of rate and extent of drug ab-
sorption (Du et al., 2018). The formulation of this drug as a
nanosystem augmented its solubility and permeability (Xie et al.,
2011). In addition, PLGA NPs can reach systemic circulation through
gut‐associated lymphatic transport, and thus minimizes the hepatic
metabolism of the drug (Ahmad et al., 2015). The greater the lip-
ophilicity of nanosystems, the higher the extent of lymphatic trans-
port. These hypotheses, individual and/or in combination, could have
donated to the optimization of the bioavailability of ZP from PLGA
NPs (Dahan & Hoffman, 2008).
3.5.2 | Assessment of plasma GABA level
The pharmacological activity of ZP depends upon its mechanism of
action on (GABA‐A) receptors in the brain which increased the GABA
concentration (Sanger, 2004). Herein, the plasma GABA level of
different animal groups receiving different ZP formulations was
measured using a specific rabbit ELISA kit, and the results were
represented in Figure 6. The average plasma GABA level of animals
treated with ZP‐PLGA NPs (F5) was significantly (p ˂ 0.001) higher
concerning the GABA level of animals treated with either ZP sus-
pension or ZP marketed tablet. The results confirmed the superior
biological activity of ZP‐PLGA NPs compared to ZP suspension and
ZP marketed tablet. This might be attributed to better systemic
absorption and higher oral bioavailability of drug‐loaded NPs
compared to other ZP formulations.
3.5.3 | Assessment of sedative and hypnotic effect
ZP is used for the treatment of insomnia due to its agonist effect on
the GABA receptor as it indorses sleeping by enhancing the effect of
GABA as an inhibitory neurotransmitter (Sanger, 2004). The average
onset and duration of hypnosis were measured for animal groups
T A B L E 2 Pharmacokinetic parameters after oral administration of different zaleplon formulation
ZP formulation Cmax (ng/ml) Tmax (h) AUCtot (ng·h/ml) MRT (h) T1/2 (h
¡1)
ZP marketed tablet 10.86 � 2.05 1.0 � 0.0 625 � 34.9 6.7 � 1.38 2.14 � 1.38
ZP suspension 13.27 � 1.88 1.0 � 0.0 774 � 65.6 7.9 � 2.34 2.79 � 1.89
ZP‐PLGA NPs (F5) 29.31 � 3.08*** 2.0 � 0.0 2135 � 345*** 13.75 � 3.48*** 8.25 � 3.19***
Note: Values are mean � SEM for (n ¼ 6).
Abbreviations: AUC, area under curve; MRT, mean residence time; NP, nanoparticle; ZP‐PLGA, zaleplon–poly (dl‐lactic‐co‐glycolic acid).
***p < 0.001 compared with ZP marketed tablet and ZP suspension.
F I G U R E 5 Plasma – the concentration–time curve of zaleplon
(ZP) after oral administration of 1 mg/kg of different ZP
formulations to rabbits. Values are mean � SEM for (n ¼ 6).
***p < 0.001 compared with ZP marketed tablet and ZP suspension.
SEM, standard error mean
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treated with different ZP formulations and the results were
demonstrated in Figure 7. Animals treated with different ZP formu-
lations showed comparable onset of hypnosis (p ˃ 0.05) (Figure 7a).
However, animals treated with ZP‐PLGA NPs exhibited significantly
(p ˂ 0.05) prolonged duration of hypnosis compared to other ZP
formulations (Figure 7b). The hypnotic action of ZP lasted for longer
duration in the rabbits treated with NPs formulations due to sus-
tained release of ZP from PLGA NPs, which resulted in longer drug
residences in the systemic circulation (Dudhipala & Janga, 2017). The
sedative and hypnotic effects of different ZP treatments were highly
agreed with our previous results of plasma GABA levels. Animals
treated with ZP‐loaded NP showed a prolonged sleep duration due to
high plasma GABA level compared to animals treated with ZP sus-
pension or ZP‐marketed tablet which showed significantly lower
GABA level and thereby shorter sleep duration.
3.5.4 | Evaluation of anticonvulsant activity
The MES model is used for generalized tonic–clonic seizures. This
epilepsy model was used to show the efficacy of antiepileptic agents
against partial and generalized seizure types. The MES screening tool
is useful because it can provide a quick prediction of the anticon-
vulsant activity of tested drugs with minimal investment and expe-
rience (MareŠ & KubovÁ, 2006). In vivo results were represented in
Figure 8. A high seizure score was observed for animals treated with
free ZP, which was nonsignificant from the control group (p ˃ 0.05)
(Figure 8a). A significant decrease in the stage of seizure was
observed in the case of animals that received ZP‐PLGA NPs
(p ˂ 0.001). The incidence of tonic convulsion was represented for
each group (Figure 8b). The number of rats showed tonic seizures/
total rats used and % incidence was calculated for each group of rats.
It is clear that ZP‐PLGA NPs exhibit a significant decline (p ˂ 0.001)
in the number of convulsed rats with subsequent improvement in %
incidence compared to ZP free suspension. Moreover, a marked
decrease in the duration of tonic seizures (p ˂ 0.001) was observed
for animals treated with drug‐loaded NPs compared to control and
animal treated with free ZP (Figure 8c). This augmented antiepileptic
effect of ZP‐PLGA NPs may contribute to the prolonged systemic
circulation and sustained drug release from ZP‐PLGA NPs, which
sustains its pharmacological effect. On the contrary, ZP free sus-
pension is rapidly eliminated from the blood due to its very short
elimination half‐life.
4 | CONCLUSIONS
The novelty of this study is the usage of biocompatible PLGA PNPs
for oral and parenteral administration of ZP, and in vivo evaluation
of its pharmacokinetic behavior and pharmacological activity which
is being documented for the first time. Optimizing the physico-
chemical properties of ZP‐PLGA NPs can be achieved through
F I G U R E 6 Plasma level of gamma‐aminobutyric acid after oral
administration of 1 mg/kg of different Zaleplon (ZP) formulations to
rabbits. Values are mean � SEM for (n ¼ 6). ***p < 0.001 compared
with ZP marketed tablet and ZP suspension
F I G U R E 7 Evaluation of sedative and hypnotic effect oral
administration of 1 mg/kg of different Zaleplon (ZP) formulations to
rabbits; (a) onset of hypnosis; (b) duration of hypnosis. Values are
mean � SEM for (n ¼ 6). *p < 0.05 compared with ZP marketed
tablet and ZP suspension
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adjusting different process variables, especially the polymer con-
centration, stabilizer concentration, and time of sonication. Opti-
mum ZP‐PLGA NPs showed a small size of 200 nm and a high
entrapment efficiency of 96%. ZP‐PLGA NPs exhibited a significant
increase in oral bioavailability represented by higher Cmax and AUC
values compared to ZP suspension and ZP marketed tablet. Opti-
mum ZP‐PLGA NPs showed significantly longer MRT and T1/2
compared to other ZP formulations. The bioavailability of ZP was
increased by more than threefold compared to ZP marketed tablet.
Furthermore, in vivo results reinforced the enhanced biological ac-
tivity of ZP‐PLGA NPs represented by its superior sedative and
hypnotic effect compared to the conventional dosage form. The
parenteral administration of ZP‐loaded NPs exhibited a potent
anticonvulsant activity concerning the free drug. In conclusion, our
results indicate that the ZP‐PLGA nanoparticulate system is a
hopeful formulation strategy for the improvement of ZP oral and
parenteral administration.
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